Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Rheumatoid arthritis

Autoantibody testing to predict response to therapy in RA

Nature Reviews Rheumatology volume 12, pages 566–568 (2016)Cite this article

Subjects

New research shows that an extended autoantibody repertoire is associated with adverse clinical outcomes in patients with rheumatoid arthritis. Testing for rheumatoid factor and antibodies against citrullinated proteins is now routine in the evaluation of patients with rheumatoid arthritis; should this testing be extended to include other classes of autoantibody?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The breadth of the anti-modified protein antibody response determines the risk of relapse when tapering DMARD therapy in patients with rheumatoid arthritis.

References

  1. Figueiredo, C. P. et al. Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2016-209297 (2016).

  2. Willemze, A., Trouw, L. A., Toes, R. E. & Huizinga, T. W. The influence of ACPA status and characteristics on the course of RA. Nat. Rev. Rheumatol. 8, 144–152 (2012).

    Article  CAS  Google Scholar 

  3. van der Woude, D. et al. The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis. Ann. Rheum. Dis. 69, 1110–1116 (2010).

    Article  CAS  Google Scholar 

  4. Isaacs, J. D. et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann. Rheum. Dis. 72, 329–336 (2013).

    Article  CAS  Google Scholar 

  5. Sokolove, J. et al. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann. Rheum. Dis. 75, 709–714 (2016).

    Article  CAS  Google Scholar 

  6. van der Woude, D. et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum. 60, 2262–2271 (2009).

    Article  Google Scholar 

  7. Shi, J. et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc. Natl Acad. Sci. USA 108, 17372–17377 (2011).

    Article  CAS  Google Scholar 

  8. Juarez, M. et al. Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis. Ann. Rheum. Dis. 75, 1099–1107 (2016).

    Article  CAS  Google Scholar 

  9. Thiele, G. M. et al. Malondialdehyde-acetaldehyde adducts and anti-malondialdehyde-acetaldehyde antibodies in rheumatoid arthritis. Arthritis Rheumatol. 67, 645–655 (2015).

    Article  CAS  Google Scholar 

  10. Markusse, I. M. et al. Long-term outcomes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment: a randomized trial. Ann. Intern. Med. 164, 523–531 (2016).

    Article  Google Scholar 

Download references

Acknowledgements

The work of L.A.T. and R.E.M.T. is supported by the Molecular Diagnostics in Rheumatoid Arthritis project (40-43600-98-14001); the Innovative Medicines Initiative Joint Undertaking funded project, Be The Cure (115142–2); the Dutch Arthritis Foundation and The Netherlands Organization for Scientific Research.

Author information

Authors and Affiliations

  1. Department of Rheumatology, Leiden University Medical Centre, Albinusdreef 2, Leiden, 2333, ZA, Netherlands

    Leendert A. Trouw & Rene E. M. Toes

Authors
  1. Leendert A. Trouw
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rene E. M. Toes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leendert A. Trouw.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Trouw, L., Toes, R. Autoantibody testing to predict response to therapy in RA. Nat Rev Rheumatol 12, 566–568 (2016). https://doi.org/10.1038/nrrheum.2016.151

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2016.151

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research